Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Acarbose [trade name: Glucobay, Precose, Prandase]and probiotic Lactobacillus rhamnosus (ALR) increases the expression of tumor suppressor genes, such as TPM1(Tropomycin1), TIMP3 (TIMP Metallopeptidase Inhibitor 3),  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer progression, via up-regulation of its target gene, 16/January/2019, 12.11 am

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Acarbose [trade name: Glucobay, Precose, Prandase]and probiotic Lactobacillus rhamnosus (ALR) increases the expression of tumor suppressor genes, such as TPM1(Tropomycin1), […]

Treating advanced cancers resistant to Paclitaxel/Topotecan/Temozolomide: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and in other advanced metastatic cancers resistant to Paclitaxel/Topotecan/Temozolomide: A pharmaceutical mixture encompassing Veliparib (ABT-888) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, BIRC5, p53, and TA-p73/p63, INK4a and others, decreases PP2A expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Paclitaxel/Topotecan/Temozolomide, and stalls advanced ovarian cancers  progression, and prolongs survival, via up-regulation of its target gene, 29/November/2019, 4.20 pm

Introduction: What they say A study from the Department of Gynecologic Oncology and Reproductive Medicine,  University of Texas M.D. Anderson Cancer Center, 1155 Pressler Dr., Houston, TX 77030, USA, and others states that “Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.“ This research paper was published, in the 28 September 2019 issue of the journal “N Engl J Med. (one […]

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PIAS3, VHL, p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 8/November/2019, 6.39 pm

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA highlights the role of “Docomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib“ This research paper was published, in the 3 […]

Treating advanced cancers resistant to Paclitaxel/Topotecan/Temozolomide: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancers and in other advanced metastatic cancers resistant to Paclitaxel/Topotecan/Temozolomide: A pharmaceutical mixture encompassing Veliparib (ABT-888) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Paclitaxel/Topotecan/Temozolomide, and stalls advanced ovarian cancers  progression, and prolongs survival, via up-regulation of its target gene, 7/November/2019, 11.59 pm

Introduction: What they say A study from the Department of Gynecologic Oncology and Reproductive Medicine,  University of Texas M.D. Anderson Cancer Center, 1155 Pressler Dr., Houston, TX 77030, USA, and others states that “Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.“ This research paper was published, in the 28 September 2019 issue of the journal “N Engl J Med. (one […]

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 21/October/2019, 10.31 pm

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA highlights the role of “Docomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib“ This research paper was published, in the 3 […]

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 13/October/2019, 12.55 am

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA highlights the role of “Docomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib“ This research paper was published, in the 3 […]